

Ref: Akums/Exchange/2026-27/08

May 14, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Mumbai - 400 001

Symbol: AKUMS

Scrip Code: 544222

Sub: Outcome of Board Meeting held on May 14, 2026

Respected Sir/Madam,

In terms of Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Akums Drugs and Pharmaceuticals Limited ("the Company") at their meeting held today i.e. Thursday, May 14, 2026 has inter-alia considered and approved the followings:

1. The Un-audited (Standalone & Consolidated) Financial Results for the quarter ended March 31, 2026, and Audited (Standalone & Consolidated) Financial Results for the year ended March 31, 2026, along with the Audit Reports thereon, as received from the Statutory Auditors, Walker Chandiook & Co. LLP, Chartered Accountants. Copies of such financial results along with the Audit Reports thereon are enclosed herewith as **Annexure-A**.

Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is enclosed herewith as **Annexure-A1**.

Statement of Deviation for the quarter ended March 31, 2026 is enclosed herewith as **Annexure- B**.

2. Recommended a Final Dividend of Rs. 1.00/- per equity share and a special dividend of Rs. 2.00/- per equity share for the Financial Year ended March 31, 2026 and fixation of record date.

The Board of Directors have recommended a final dividend of Rs. 1.00/- (@ 50%) per equity share and a special dividend of Rs. 2.00/- (@ 100%) per equity share having face value of Rs. 2/- (Rupees Two) each fully paid-up for the Financial Year ended March 31, 2026, subject to the approval of the Shareholders of the Company at the ensuing Annual General Meeting.

Further, as per Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has fixed Friday, July 03, 2026 as the **'Record Date'** to ascertain the eligibility of the shareholders for the payment of final & special dividend.

The Final & special Dividend, if approved by the shareholders at the ensuing 22nd Annual General Meeting, will be paid within 30 days from the date of approval by the Shareholders of the Company.

3. Re-appointment of M/s. Balwinder & Associates, Cost Accountants as Cost Auditors of the Company for the F.Y. 2026-27 on a remuneration of Rs.3,00,000/- subject to the ratification of shareholders at the ensuing Annual General Meeting of the Company.

Details required pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as **Annexure-C**.

4. Appointment of Mahajan & Aibara LLP, Chartered Accountants as Internal Auditors of the Company for the F.Y. 2026-27

Details required pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as **Annexure-D**.

5. Changes in Senior Management Personnel of the Company w.e.f. May 14, 2026

On the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company has approved the following:

- a) Appointment of Mr. V Jagannathan, President - HR as Senior Management Personnel of the Company.
- b) Cessation of Mr. Arvind Srivastava, President - HR as Senior Management Personnel of the Company.

Details required pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as **Annexure-E**.

6. Notice of the 22nd Annual General Meeting (AGM) of the Company, scheduled to be held on Friday, July 10, 2026 at 11:00 AM IST through Video Conferencing/ Other Audio-Visual Means. The notice convening the AGM along with the Integrated Annual Report for the financial year ended March 31, 2026, will be sent in due course.

The Board Meeting commenced at 11.30 A.M. and concluded at 01.09 P.M.

This is for your kind information and record.

Thanking You

Yours Faithfully

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik
Company Secretary & Compliance Officer

Encl: As Above

Walker Chandiook & Co LLP
 L 41, Connaught Circus,
 Outer Circle,
 New Delhi – 110 001
 India
 T +91 11 45002219
 F +91 11 42787071

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Akums Drugs and Pharmaceuticals Limited

Opinion

1. We have audited the accompanying standalone annual financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Company') for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit report of the other auditor on separate financial statements on Akums Employee Benefit Trust ("the Trust") as referred to in paragraph 12 below, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2026.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditors, in terms of their reports referred to in paragraph 12 of the Other Matter section below, is sufficient and appropriate to provide a basis for our opinion.



Walker ChandioK & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (contd.)

Emphasis of Matter – Search and Seizure

4. We draw attention to note 6 to the accompanying standalone financial results relating to a search and seizure operation carried out by the Income Tax Department during the financial year ended 31 March 2025 at certain offices and manufacturing units of the Company and its subsidiaries, and the residences of selected key managerial personnel of the Company from 15 January 2025 to 21 January 2025 under Section 132 of the Income Tax Act, 1961 ('Tax Act'). The Company has complied with notices issued by the income tax authorities from time to time in this regard. Subsequent to the quarter and year ended 31 March 2026, the Company has received show cause notice (SCN) under section 158BC of the Tax Act and is in the process of submitting its response thereto. Pending conclusion of the ongoing search and seizure proceedings, the impact of this matter on the standalone financial results for the quarter and year ended 31 March 2026 and the adjustments (if any) required, is presently not ascertainable.

Our opinion is not modified in respect of this matter.

Responsibilities of Management and Those Charged with Governance for the Statement

5. This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
6. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
7. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

8. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
9. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



Walker ChandioK & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (contd.)

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
 - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation. ; and
 - Obtain sufficient appropriate audit evidence regarding the business activities and financial information of the Company which includes financial information of its Trust, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of the Company of which we are the independent auditors. For the Trust included in the Statement, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

12. We did not audit the financial statements of Akums Employee Benefit Trust ("the Trust") included in the standalone results of the Company whose financial statements reflects total assets of ₹ 3,004.38 as at 31 March 2026, and the total revenues of ₹ nil, total net loss after tax of ₹ 0.01 million, total comprehensive income of ₹ 0.01 million and net cash inflows of ₹ 0.03 for the year ended on that date. The standalone results also include the Company's share in the net profit (including other comprehensive income) of ₹ 50.06 million for the year ended 31 March 2026 in respect of 1 Limited Liability Partnership (LLP), whose financial statements have not been audited by us. These financial statements of the Trust and LLP have been audited by the other auditor, whose reports have been furnished to us by the management, and our opinion on the standalone financial results, in so far as it relates to the amounts and disclosures included in respect of these Trust and LLP, and our report in



Walker ChandioK & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (contd.)

terms of Sub-section (3) of Section 143 of the Act in so far as it relates to the aforesaid Trust and LLP, is based solely on the reports of such other auditor.

Further, the aforementioned financial statements and other financial information of the Trust and LLP have been prepared in conformity with the Accounting Standards specified under Section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021 and other accounting principles generally accepted in India ('IGAAP'). The Company's management has converted the financial statements of the Trust and LLP from IGAAP to accounting principles enunciated under Ind AS specified under Section 133 of the Act and other accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's management. Our opinion on the standalone financial results, in so far as it relates to the amounts and disclosures included in respect of Trust and LLP, is based on the reports of other auditors and the conversion adjustments prepared by the management of the Company and audited by us.

Our opinion above on the standalone financial results, and our report on other legal and regulatory requirements below, are not modified in respect of the above matters with respect to our reliance on the work done by and the reports of the other auditor.

13. The Statement includes the standalone financial results for the quarter ended 31 March 2026, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Walker ChandioK & Co LLP
Chartered Accountants
Firm Registration No.: 001076N/N500013

Tarun

Tarun Gupta
Partner
Membership No. 507892
UDIN: 26507892JOWJDA3516



Place: New Delhi
Date: 14 May 2026

Statement of audited standalone financial results for the quarter and year ended 31 March 2026

(₹ in million, unless otherwise stated)

S. No.	Particulars	Quarter ended			Year ended	
		31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
		(refer note 3)	Unaudited	(refer note 3)	Audited	Audited
I	Income					
	Revenue from operations	3,383.72	3,686.06	3,287.53	13,487.36	13,117.84
	Other income	277.29	296.04	320.50	1,129.65	1,241.92
	Total income (I)	3,661.01	3,982.10	3,608.03	14,617.01	14,359.76
II	Expenses					
	Cost of materials consumed	2,128.09	2,226.69	2,070.63	8,303.42	8,110.58
	Changes in inventories of finished goods and work-in-progress	(61.45)	117.11	3.49	(32.58)	(100.50)
	Employee benefits expense	578.78	547.99	538.36	2,179.93	2,017.36
	Finance costs	25.93	24.57	26.26	100.38	153.09
	Depreciation and amortisation expense	124.21	121.46	100.93	455.03	395.45
	Fair value changes to financial instruments	-	-	-	-	(38.67)
	Other expenses	620.43	547.53	497.81	2,061.99	1,744.08
	Total expenses (II)	3,415.99	3,585.35	3,237.48	13,068.17	12,281.39
III	Profit before exceptional items and tax (I-II)	245.02	396.75	370.55	1,548.84	2,078.37
IV	Exceptional items (refer note 9)	27.11	38.08	-	65.19	-
V	Profit before tax for the quarter/ year (III-IV)	217.91	358.67	370.55	1,483.65	2,078.37
VI	Tax expense					
	Current tax					
	for current quarter/ year	32.66	99.91	82.61	377.93	492.74
	for earlier years	-	(13.92)	-	(13.92)	3.90
	Deferred tax (credit)/ charge					
	for current quarter/ year	33.28	(15.39)	12.05	(3.69)	(7.14)
	for earlier years	-	6.93	-	6.93	(21.11)
	Total tax expense	65.94	77.53	94.66	367.25	468.39
VII	Profit for the quarter/ year (V-VI)	151.97	281.14	275.89	1,116.40	1,609.98
VIII	Other comprehensive income					
	Items that will not be reclassified to statement of profit and loss					
	Re-measurement gains/(losses) on defined benefit plans	11.01	3.82	(0.77)	6.21	(0.96)
	Tax effect relating to these items	(2.77)	(0.96)	0.19	(1.56)	0.24
	Other comprehensive income, net of tax	8.24	2.86	(0.58)	4.65	(0.72)
IX	Total comprehensive income for the quarter/ year (VII+VIII) (comprising profit for the quarter/ year and other comprehensive income, net of tax)	160.21	284.00	275.31	1,121.05	1,609.26
X	Paid-up share capital (net off shares held by ESOP trust) (refer note 8)	306.21	306.21	306.21	306.21	306.21
XI	Other equity				23,969.46	22,746.26
XII	Earning per share (EPS) (face value of ₹ 2/- each) (in ₹)*					
	Basic and diluted	0.99	1.84	1.80	7.29	10.76

*EPS for the quarters have not been annualised



Particulars	As at	As at
	31 March 2026	31 March 2025
	Audited	Audited
ASSETS		
(1) Non-current assets		
(a) Property, plant and equipment	3,314.50	2,647.05
(b) Right-of-use assets	720.82	702.12
(c) Capital work-in-progress	515.67	537.11
(d) Investment property	181.13	184.88
(e) Intangible assets	33.96	26.02
(f) Intangible assets under development	6.60	30.24
(g) Financial assets		
(i) Investments	3,660.17	3,660.14
(ii) Loans	6,084.78	10,443.39
(iii) Others financial assets	91.38	100.44
(h) Non-current tax assets (net)	74.87	58.59
(i) Other non-current assets	205.93	127.31
Total non-current assets	14,889.81	18,517.29
(2) Current assets		
(a) Inventories	2,299.26	2,016.89
(b) Financial assets		
(i) Trade receivables	2,175.42	2,061.37
(ii) Cash and cash equivalents	463.84	764.92
(iii) Bank balances other than (ii) above	7,245.60	2,796.25
(iv) Others financial assets	232.63	204.87
(c) Other current assets	818.22	487.51
Total current assets	13,234.97	8,331.81
Total assets	28,124.78	26,849.10
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	306.21	306.21
(b) Other equity	23,969.46	22,746.26
Total equity	24,275.67	23,052.47
Liabilities		
(1) Non-current liabilities		
(a) Financial liabilities		
(i) Lease liability	439.29	401.77
(ii) Other financial liabilities	126.66	97.84
(b) Provisions	163.76	129.31
(c) Deferred tax liabilities (net)	79.45	74.63
Total non-current liabilities	809.16	703.55
(2) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	135.52	39.30
(ii) Lease liability	17.33	21.80
(iii) Trade payables		
Total outstanding dues to micro and small enterprises; and	287.14	225.20
Total outstanding dues of creditors other than micro and small enterprises	1,726.90	1,970.35
(iv) Other financial liabilities	632.44	684.12
(b) Other current liabilities	136.93	94.78
(c) Provisions	79.88	57.11
(d) Current tax liabilities (net)	23.81	0.42
Total current liabilities	3,039.95	3,093.08
Total equity and liabilities	28,124.78	26,849.10



(₹ in million, unless otherwise stated)

Particulars	Year ended	
	31 March 2026	31 March 2025
	Audited	Audited
A. Cash flow from operating activities		
Net profit before tax	1,483.65	2,078.37
Adjustments for:		
Depreciation and amortisation expense	455.03	395.45
Fair value changes on financial instruments	-	(38.67)
Provision for expected credit loss on trade receivable	167.37	74.01
Provision on advance to suppliers	7.29	20.00
Loss on sale of property, plant and equipment (net)	0.34	0.56
Finance costs	100.38	153.09
Interest income	(1,007.33)	(973.11)
Gain on reassessment of right-of-use assets	(0.08)	(34.79)
Liability no longer required written back	(2.66)	(37.36)
Share of profit from investment in Limited Liability Partnership (LLP)	(50.06)	(85.89)
Rental income	(39.17)	(39.94)
Employee discount on issue of shares	-	15.60
Income tax refund receivable	-	(19.25)
Unrealised foreign exchange differences (net)	(2.68)	0.27
Operating profit before working capital changes	1,112.08	1,508.34
Adjustments for movement in working capital changes:		
Increase in inventories	(282.37)	(399.86)
(Increase)/ decrease in trade receivables	(281.42)	202.56
Decrease in other financial assets	26.78	35.75
Increase in other assets	(327.10)	(87.82)
(Decrease)/ increase in trade payables	(74.02)	583.50
Increase/ (decrease) in other financial liabilities	57.43	(400.59)
Increase in provisions	63.43	17.95
Increase/ (decrease) in other liabilities	42.15	(61.12)
Cash flow generated from operations	336.96	1,398.71
Less: taxes paid (net)	(358.43)	(488.69)
Net cash flow (used in)/ generated from operating activities (A)	(21.47)	910.02
B. Cash flow from investing activities		
Purchase of property, plant and equipment and intangible assets (including investment property, capital work-in-progress, capital advances and payable towards property, plant and equipment)	(1,220.72)	(956.18)
Proceeds from sale of property plant and equipment	10.76	20.23
Investment in subsidiaries	(0.03)	(2,270.90)
Investment in deposits having original maturity of more than 3 months (net)	(4,062.74)	(2,750.87)
Loan given to subsidiary companies / LLP	(4,993.21)	(16,556.01)
Loan repaid by subsidiary companies / LLP	9,323.74	16,829.30
Withdrawals from partnership firm	-	82.96
Interest received	653.37	973.11
Rent received	39.17	39.94
Net cash flow used in investing activities (B)	(249.66)	(4,588.43)
C. Cash flow from financing activities		
Proceeds from issue of shares (net of share issue expenses)	-	6,373.70
Repayment of non-current borrowings	-	(218.75)
Proceeds from/ (repayment) of current borrowings (net)	96.22	(2,004.81)
Payment of principal components of lease liabilities	(27.32)	(243.29)
Payment of interest components of lease liabilities	(40.41)	(31.01)
Interest paid	(58.44)	(122.08)
Net cash flow (used in)/ generated from financing activities (C)	(29.95)	3,753.76
Net increase in cash and cash equivalents (A+B+C)	(301.08)	75.35
Cash and cash equivalents at the beginning of the year	764.92	689.57
Cash and cash equivalents at the end of the year	463.84	764.92

Notes :-

The above audited standalone statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7 - Statement of Cash Flows.



Notes:

- The above standalone financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 14 May 2026. These standalone financial results for the quarter and year ended 31 March 2026 have been audited by statutory auditor and they have issued an unmodified report on the aforementioned results.
- These standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).
- The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures for the respective full financial years ended 31 March 2026 and 31 March 2025 and unaudited published figures upto the nine months periods of the respective financial years, which were subject to the limited review by statutory auditors of the Company.
- The Company had completed its Initial Public Offer (IPO) of 27,368,143 equity shares of face value of ₹ 2 each at an issue price of ₹ 679 per share (including share premium of ₹ 677 per share). A discount of ₹ 64 per share was offered to eligible employees bidding in the employee reservation portion of 243,826 equity shares. Pursuant to IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 6 August 2024. The issue comprised of fresh issue of 10,037,708 equity shares aggregating to ₹ 6,800.00 million and offer for sale of 17,330,435 equity shares by selling shareholders, aggregating to ₹ 11,767.37 million.

IPO related expenses were earlier estimated at ₹ 1,116.58 million and were allocated between the Company and the selling shareholders in proportion to their respective shares in the issue. The Company, during the quarter ended 31 March 2026 had incurred IPO expenses amounted to ₹ 990.61 million till date as against the earlier estimated expenses of ₹ 1,116.58 million as disclosed in the Prospectus, resulting in an excess provision of ₹ 125.98 million. The IPO expenses were initially withheld from the IPO proceeds and were allocated between the Company and the selling shareholders in proportion to their respective shares in the issue. Accordingly, the excess amount of ₹ 125.98 million is being released proportionately to the Company and the selling shareholders.

Pursuant to the Board resolution dated 13 February 2026, out of the excess amount attributable to the Company, ₹ 48.10 million has been reallocated towards the objects of the issue, comprising ₹ 23.10 million towards pursuing inorganic growth initiatives through acquisitions and ₹ 25.00 million towards general corporate purposes. The balance amount attributable to the selling shareholders is being released to them in proportion to their respective entitlements. Accordingly, the utilisation of the net IPO proceeds, after the aforesaid reallocation, is summarised below:

Objects	Revised net proceeds as per prospectus*	Actual net proceeds*	Utilisation upto 31 March 2026	Unutilised amount as on 31 March 2026
Repayment/prepayment of all or certain borrowings of the Company	1,599.10	1,599.10	1,599.10	-
Repayment/prepayment of all or certain borrowings of the subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2,270.90	2,270.90	2,270.90	-
Funding incremental working capital requirements of the Company	550.00	550.00	550.00	-
Pursuing inorganic growth initiatives through acquisitions	301.80	301.80	278.70	23.10
General corporate purposes	1,700.00	1,700.00	1,675.00	25.00
Total proceeds (net of IPO expenses)	6,421.80	6,421.80	6,373.70	48.10

* includes ₹ 48.10 million arising from the reallocation of excess IPO expenses provision as explained above, resulting in a corresponding increase in the actual net proceeds available for utilisation.

- The Company operates in only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segment is not applicable and accordingly not made.
- During the financial year ended 31 March 2025, from 15 January 2025 to 21 January 2025, the Income Tax Department ("IT Department") has conducted a search and seizure operation under Section 132 of the Income Tax Act, 1961, at certain offices and manufacturing units of the Company and its subsidiaries, and the residences of selected key managerial personnel of the Company and its subsidiaries.

During the search and seizure proceedings, the Company has fully cooperated, provided the required information and responses to the IT Department. As a part of search and seizure operation, the IT Department has cloned electronic books of accounts, laptops, data backups and seized certain documents, cash and other materials for further investigation. The business and operations of the Company continued without any disruptions, except some minor operational hiccups, and customer commitments were met during this period. During the current year, the Company has received notice under Section 158BC of the Income tax Act, 1961, which requires the Company, in consequence of aforesaid search and seizure operations initiated under Section 132, to furnish returns of undisclosed income for the relevant block period from 01 April 2018 to 12 March 2025 in the prescribed form and manner as per rule 12AE of Income-tax Rules, 1962 setting forth such other particulars as may be prescribed by the Income-tax Act, 1961 within 60 days from the date of notice. The Company has assessed that no undisclosed income is required to be reported and accordingly, has filled the said returns during the year. Further, the Company has received notice under Section 142(1)/143(2) of the Income Tax Act, 1961 to furnish accounts or documents or information in response thereto for the aforesaid block period for which notices have been issued. The Company has submitted the said details in compliance to the said notice.

Subsequent to the quarter/year ended 31 March 2026, the Company has received show cause notices ("SCN") dated 5 May 2026, in relation to the ongoing block assessment proceedings under Section 158BC of the Income Tax Act, 1961 for the block period in relation to certain disallowance of expenses for which the Company is in the process of submitting its response to the IT Department.

Further, there have been no demands which have been raised on the Company as of date. Based on the foregoing and having regard to the matters of the inquiry during the search and seizure proceedings stated above including the SCN and the legal opinion obtained by the management for matters of admissibility under Income Tax Act, 1961, as applicable, while the proceedings are ongoing by the IT Department, the management is of the view that no material adjustments are required to these standalone financial results/statements for the quarter and year ended 31 March 2026 in this regard.

- The Board of Directors at its meeting held on 14 May 2026 has recommended a final dividend of ₹ 1 per equity share and special dividend of ₹ 2 per equity share for the year ended 31 March 2026, subject to the approval of shareholders at the ensuing Annual General Meeting.
- The Akums Employee Benefits Trust ("ESOP Trust") has been treated as an extension of the Company and accordingly, shares held by ESOP Trust are netted off from the paid up share capital and calculation of earnings per share (basic and diluted) have been done accordingly. Further, all the assets, liabilities, income and expenses of the ESOP Trust are accounted for as assets, liabilities, income and expenses of the Company.

(This space has been intentionally left blank)



9 During the quarter and year ended 31 March 2026, the Company recognised exceptional items, comprising the following:

Particulars	Quarter ended		Year ended
	31 March 2026	31 December 2025	31 March 2026
Impact of changes in labour code (refer note (a) below)	14.24	38.08	52.32
Retrospective wage revision/ variable dearness allowance (VDA) arrears (refer note (b) below)	12.87	-	12.87
Total	27.11	38.08	65.19

(a) On 21 November 2025, the Government of India notified the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020, thereby consolidating 29 existing labour laws. The Company has assessed the incremental impact of these changes. Considering the material and non-recurring nature of the impact, the additional charge relating to gratuity and compensated absences has been disclosed under 'Exceptional items' in these standalone financial results for the quarter and year ended 31 March 2026. The Company will continue to evaluate the impact of future regulatory clarifications and Rules.

(b) Subsequent to the quarter and year ended 31 March 2026, the Government of Uttarakhand revised the Variable Dearness Allowance ("VDA") rates for scheduled employments with retrospective effect. Accordingly, the cumulative impact relating to prior periods has been recognised as a liability as at 31 March 2026 and disclosed under 'Exceptional items' in these standalone financial results for the quarter and year ended 31 March 2026.



Place: New Delhi
Date: 14 May 2026



For and on behalf of Board of Directors of
Akums Drugs and Pharmaceuticals Limited

Sanjeev Jain
Managing Director
DIN: 00323433

Walker Chandiook & Co LLP
L 41, Connaught Circus,
Outer Circle,
New Delhi – 110 001
India
T +91 11 45002219
F +91 11 42787071

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Akums Drugs and Pharmaceuticals Limited

Opinion

1. We have audited the accompanying consolidated annual financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate audited financial statements/ financial information of the subsidiaries, as referred to in paragraph 13 below, the Statement:
 - (i) includes the annual financial results of the entities listed in Annexure 1;
 - (ii) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations,; and
 - (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group, for the year ended 31 March 2026.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in *the Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the consolidated financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 13 of the Other Matter section below, is sufficient and appropriate to provide a basis for our opinion.



Walker Chandiook & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (contd.)

Emphasis of Matter - Search and Seizure

4. We draw attention to note 8 to the accompanying consolidated financial results relating to a search and seizure operation carried out by the Income Tax Department during the financial year ended 31 March 2025 at certain offices and manufacturing units of the Holding Company and its subsidiaries, and the residences of selected key managerial personnel of the Group from 15 January 2025 to 21 January 2025 under Section 132 of the Income Tax Act, 1961 ('Tax Act'). The Company has complied with notices issued by the income tax authorities from time to time in this regard. Subsequent to the quarter and year ended 31 March 2026, the Holding Company and few of its subsidiaries have received show cause notices (SCN) under section 158BC of the Tax Act and is in the process of submitting its response thereto. Pending conclusion of the ongoing search and seizure procedures the impact of this matter on the consolidated financial results for the quarter and year ended 31 March 2026 and the adjustments (if any) required, is presently not ascertainable.

The above matter has also been reported as an emphasis of matter in the audit reports dated 07 May 2026, 08 May 2026 and 09 May 2026 issued by another firm of chartered accountants on the financial statements of 3 subsidiaries of the Holding Company.

Our opinion is not modified in respect of this matter.

Responsibilities of Management and Those Charged with Governance for the Statement

5. The Statement has been prepared on the basis of the consolidated annual financial statements and has been approved by the Holding Company's Board of Directors. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit and other comprehensive income, and other financial information of the Group in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group covered under the Act, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
6. In preparing the Statement, the respective Board of Directors of the companies included in the Group, are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
7. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group.



Walker Chandiook & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (contd.)

Auditor's Responsibilities for the Audit of the Statement

8. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
9. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
 - Conclude on the appropriateness of Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern;
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation; and
 - Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement, of which we are the independent auditors. For the other entities included in the Statement, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
10. We communicate with those charged with governance of the Holding Company and such other entities included in the Statement, of which we are the independent auditors, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Walker Chandiook & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (contd.)

12. We also performed procedures in accordance with circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matters

13. We did not audit the financial statements of 8 subsidiaries, whose financial statements reflects total assets of ₹ 5,220.39 million as at 31 March 2026, total revenues of ₹ 2,221.42, total net loss after tax of ₹ 820.06 million, total comprehensive loss of ₹ 822.18 million, and net cash inflows amounting to ₹ 30.50 million for the year ended on that date, as considered in the statements. These financial statements have been audited by other auditors whose reports have been furnished to us by the management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of sub-section (3) of Section 143 of the Act in so far as it relates to the aforesaid subsidiaries, are based solely on the reports of the other auditors.

Further, of these subsidiaries, 1 subsidiary are located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries and 1 subsidiary, being LLP, whose financial statements and other financial information has been prepared in conformity with the Accounting Standards specified under Section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021 and other accounting principles generally accepted in India ('IGAAP'). The Holding Company's management has converted, the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries and the financial statements of LLP from IGAAP, to accounting principles enunciated under Ind AS specified under Section 133 of the Act and other accounting principles generally accepted in India. We have audited these conversion adjustments made by the Holding Company's management. Our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of such subsidiaries located outside India and LLP, is based on the reports of other auditors and the conversion adjustments prepared by the management of the Holding Company and audited by us.

Our opinion above on the consolidated financial results, and our report on other legal and regulatory requirements below, are not modified in respect of the above matters with respect to our reliance on the work done by and the reports of the other auditors.

14. We did not audit the financial information of 2 subsidiaries, whose financial information reflect total assets of ₹ 0.03 million as at 31 March 2026, total revenues of ₹ nil total net profit after tax of ₹ nil, total comprehensive income of ₹ nil, and net cash inflows amounting to ₹ 0.03 for the year ended on that date, as considered in the consolidated financial results. These financial information are unaudited and have been furnished to us by the management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of the aforesaid subsidiaries, is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the management, these financial information are not material to the Group.

Our opinion is not modified in respect of this matter with respect to our reliance on the financial information certified by the Board of Directors.



Walker Chandiook & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (contd.)

15. The Statement includes the consolidated financial results for the quarter ended 31 March 2026, being the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year-to-date consolidated figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013

Tarun

Tarun Gupta

Partner

Membership No. 507892

UDIN: 26507892HMULAE2840



Place: New Delhi

Date: 14 May 2026

Walker Chandiook & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (contd.)

Annexure 1

List of subsidiaries included in the Statement

1. Pure and Cure Healthcare Private Limited
2. Malik Lifesciences Private Limited
3. Maxcure Nutravedics Limited
4. Unosource Pharma Limited
5. Akumentis Healthcare Limited
6. Sarvagunaushdhi Private Limited
7. Plenteous Pharmaceuticals Limited
8. Upadhrish Researchem LLP
9. Nicholas Healthcare Limited
10. Akums Healthcare Limited
11. Qualymed Pharma Private Limited
12. Akums Healthcare UK Limited
13. Akums Healthcare Zambia Private Limited (w.e.f. 13 October 2025)
14. Akums Healthcare Malta Private Limited (w.e.f. 20 October 2025)

Step Down Subsidiary

1. Medibox Pharma Private Limited (subsidiary of Maxcure Nutravedics Limited)



S. No.	Particulars	Quarter ended			Year ended	
		31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
		(refer note 2)	Unaudited	(refer note 2)	Audited	Audited
I	Income					
	Revenue from operations	11,578.68	11,595.87	10,555.47	43,590.17	41,181.58
	Other income	353.01	343.28	175.45	1,287.25	521.22
	Total income (I)	11,931.69	11,939.15	10,730.92	44,877.42	41,702.80
II	Expenses					
	Cost of materials consumed	5,869.06	6,112.55	6,238.45	22,986.83	22,536.08
	Purchase of stock-in-trade	629.26	602.86	194.90	2,009.97	1,814.73
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	106.30	70.36	(42.49)	138.38	(16.47)
	Employee benefits expense	1,990.32	1,893.79	1,838.97	7,538.24	7,158.21
	Finance costs (refer note 6)	238.92	237.42	45.42	940.73	346.00
	Depreciation and amortisation expense	401.18	396.49	399.97	1,545.51	1,534.46
	Fair value changes to financial instruments	-	-	-	-	(38.67)
	Other expenses	1,466.53	1,447.74	1,386.51	5,696.51	5,082.90
	Total expenses (II)	10,701.57	10,761.21	10,061.73	40,856.17	38,417.24
III	Profit before exceptional items and tax (I-II)	1,230.12	1,177.94	669.19	4,021.25	3,285.56
IV	Exceptional items (refer note 7)	17.96	182.28	(82.17)	200.24	(166.97)
V	Profit before tax for the quarter/ year (III-IV)	1,212.16	995.66	751.36	3,821.01	3,452.53
VI	Tax expense					
	Current tax					
	for current quarter/ year	184.99	285.01	186.81	905.75	813.67
	for earlier years	7.84	(15.32)	(4.88)	(7.48)	(16.18)
	Deferred tax charge/ (credit)					
	for current quarter/ year	205.91	35.98	(948.80)	345.52	(794.29)
	for earlier years	-	13.25	22.17	13.25	11.56
	Total tax expense	398.74	318.92	(744.70)	1,257.04	14.76
VII	Profit for the quarter/ year (V-VI)	813.42	676.74	1,496.06	2,563.97	3,437.77
VIII	Other comprehensive income					
	(a) Items that will not be reclassified to profit and loss					
	Remeasurements of defined benefit plans	36.42	7.49	(12.55)	13.16	(13.62)
	Income tax relating to above mentioned items	(8.57)	(0.45)	2.39	(3.90)	2.67
	(b) Items that will be reclassified to profit and loss					
	Exchange differences on translation of foreign operations	(0.01)	(0.02)	-	(0.03)	-
	Other comprehensive income, net of tax	27.84	7.02	(10.16)	9.23	(10.95)
IX	Total comprehensive income for the quarter/ year (VII+VIII) (comprising profit for the quarter/ year and other comprehensive income, net of tax)	841.26	683.76	1,485.90	2,573.20	3,426.82
X	Profit for the quarter/ year attributable to:					
	Owners of the Parent	846.13	663.17	1,476.17	2,551.88	3,381.76
	Non controlling interest	(32.71)	13.57	19.89	12.09	56.01
XI	Other comprehensive income for the quarter/ year attributable to:					
	Owners of the Parent	27.88	7.00	(10.21)	9.56	(11.03)
	Non controlling interest	(0.04)	0.02	0.05	(0.33)	0.08
XII	Total comprehensive income for the quarter/ year attributable to:					
	Owners of the Parent	874.01	670.17	1,465.96	2,561.44	3,370.73
	Non controlling interest	(32.75)	13.59	19.94	11.76	56.09
XIII	Paid-up share capital (net off shares held by ESOP trust) (refer note 5)	306.21	306.21	306.21	306.21	306.21
XIV	Other equity				32,827.27	30,163.93
XV	Earning per share (EPS) (face value of ₹ 2/- each) (in ₹)*	5.53	4.33	9.64	16.67	22.60
	Basic and diluted					

*EPS for the quarters have not been annualised



AUDITED CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES


The Group is engaged in five business segments a) Contract Development and Manufacturing operations (CDMO); b) Active Pharmaceutical Ingredient (API); c) Domestic Branded Formulations; d) International Branded Formulations and e) Trade Generics. Disclosures as per Indian Accounting Standard (Ind AS-108) "Operating Segment" has been disclosed herewith :

(₹ in million, unless otherwise stated)

Particulars	Quarter ended			Year ended	
	31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
	(refer note 2)	Unaudited	(refer note 2)	Audited	Audited
I. Revenue from operations (including inter-segment)					
a) CDMO	10,107.92	9,815.58	9,007.57	37,101.90	34,402.42
b) API	536.33	679.51	666.12	2,313.94	2,771.23
c) Domestic branded formulations	1,020.65	1,148.33	1,036.52	4,463.04	4,335.88
d) International branded formulations	358.32	501.35	396.95	1,434.62	1,426.13
e) Trade generics	275.07	247.62	231.49	1,003.27	1,178.79
	12,298.29	12,392.39	11,338.65	46,316.77	44,114.45
II. Revenue from operations (external customers)					
a) CDMO	9,519.41	9,155.93	8,397.60	34,851.99	32,078.76
b) API	407.05	542.37	501.44	1,844.35	2,192.96
c) Domestic branded formulations	1,020.65	1,148.33	1,036.52	4,463.04	4,335.88
d) International branded formulations	358.32	501.35	396.95	1,434.62	1,426.13
e) Trade generics	273.25	247.89	222.96	996.17	1,147.85
Revenue from operations	11,578.68	11,595.87	10,555.47	43,590.17	41,181.58
III. Segment results before depreciation*					
a) CDMO	1,373.27	1,258.32	886.61	4,669.31	4,538.92
b) API	(123.50)	(73.84)	(64.62)	(400.96)	(438.01)
c) Domestic branded formulations	221.07	254.59	223.49	898.00	767.25
d) International branded formulations	100.41	129.22	87.54	364.99	275.91
e) Trade generics	14.43	(32.15)	(99.11)	(101.20)	(282.17)
IV. Segment results**					
a) CDMO	1,015.68	903.63	561.38	3,290.31	3,323.83
b) API	(167.50)	(118.40)	(139.43)	(576.55)	(757.10)
c) Domestic branded formulations	211.65	248.57	217.61	872.38	745.74
d) International branded formulations	93.62	122.49	83.41	342.31	257.88
e) Trade generics	12.38	(35.12)	(104.06)	(113.93)	(306.33)
Sub total	1,165.83	1,121.17	618.91	3,814.52	3,264.02
Unallocated corporate income/ (expenses) [net]	0.60	1.60	21.35	6.40	66.32
Interest income	283.95	274.29	59.30	1,071.12	237.78
Finance costs	(220.26)	(219.12)	(30.37)	(870.79)	(282.56)
Profit before exceptional items and tax	1,230.12	1,177.94	669.19	4,021.25	3,285.56
Exceptional items	17.96	182.28	(82.17)	200.24	(166.97)
Profit before tax	1,212.16	995.66	751.36	3,821.01	3,452.53
Tax expenses	398.74	318.92	(744.70)	1,257.04	14.76
Profit for the quarter/ year	813.42	676.74	1,496.06	2,563.97	3,437.77
V. Segment assets					
a) CDMO	30,544.04	30,285.73	27,016.32	30,544.04	27,016.32
b) API	3,969.46	4,298.56	4,575.97	3,969.46	4,575.97
c) Domestic branded formulations	770.47	827.01	734.81	770.47	734.81
d) International branded formulations	929.42	853.87	813.35	929.42	813.35
e) Trade generics	456.76	485.23	739.40	456.76	739.40
Less :- Inter-segment eliminations	(916.92)	(907.99)	(735.72)	(916.92)	(735.72)
Segment assets	35,753.23	35,842.41	33,144.13	35,753.23	33,144.13
Un-allocated corporate assets	18,716.42	18,125.90	7,990.29	18,716.42	7,990.29
Total assets	54,469.65	53,968.31	41,134.42	54,469.65	41,134.42
VI. Segment liabilities					
a) CDMO	18,177.11	18,791.06	7,280.97	18,177.11	7,280.97
b) API	313.04	579.05	601.48	313.04	601.48
c) Domestic branded formulations	1,146.10	1,220.15	1,100.83	1,146.10	1,100.83
d) International branded formulations	584.24	543.76	512.21	584.24	512.21
e) Trade generics	437.71	446.75	432.80	437.71	432.80
Less :- Inter-segment eliminations	(916.92)	(907.99)	(735.72)	(916.92)	(735.72)
Segment liabilities	19,741.28	20,672.78	9,192.57	19,741.28	9,192.57
Un-allocated corporate liabilities	1,417.16	825.47	1,305.74	1,417.16	1,305.74
Total liabilities	21,158.44	21,498.25	10,498.31	21,158.44	10,498.31

* Segment results before depreciation is calculated as the sum of profit/ (loss) before tax, exceptional items, finance costs, fair value changes to financial instruments and depreciation and amortisation expense.

** Segment results is calculated as segment results before depreciation less finance costs pertaining to segments and depreciation and amortisation expense.



(₹ in million, unless otherwise stated)

Particulars	As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
ASSETS		
(1) Non-current assets		
(a) Property, plant and equipment	12,794.08	12,286.86
(b) Right-of-use assets	1,688.50	1,614.91
(c) Capital work-in-progress	1,766.64	1,596.17
(d) Goodwill	20.63	20.63
(e) Other intangible assets	54.82	51.31
(f) Intangible assets under development	7.27	31.72
(g) Financial assets		
(i) Investments	1.43	1.43
(ii) Other financial assets	293.27	335.56
(h) Non-current tax assets (net)	179.51	123.08
(i) Deferred tax assets	1,708.88	2,080.65
(j) Other non-current assets	356.04	246.01
Total non-current assets	18,871.07	18,388.33
(2) Current assets		
(a) Inventories	7,557.13	6,809.31
(b) Financial assets		
(i) Trade receivables	7,965.64	7,702.96
(ii) Cash and cash equivalents	3,860.05	1,011.91
(iii) Bank balances other than (ii) above	12,945.93	4,752.60
(iv) Other financial assets	295.71	481.28
(c) Other current assets	2,974.12	1,988.03
Total current assets	35,598.58	22,746.09
Total assets	54,469.65	41,134.42
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	306.21	306.21
(b) Other equity	32,827.27	30,163.93
Equity attributable to equity holders of the Parent	33,133.48	30,470.14
(c) Non-controlling interest	177.73	165.97
Total equity	33,311.21	30,636.11
LIABILITIES		
(1) Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	768.44	673.27
(ii) Other financial liabilities	371.24	342.44
(b) Provisions	486.07	358.97
(c) Deferred tax liabilities	177.06	186.16
(d) Other non current Liabilities	8,408.06	-
Total non-current liabilities	10,210.87	1,560.84
(2) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	729.54	136.55
(ii) Lease liabilities	76.33	72.30
(iii) Trade payables		
Total outstanding dues to micro and small enterprises; and	879.75	772.03
Total outstanding dues of creditors other than micro and small enterprises	5,141.83	5,655.82
(iv) Other financial liabilities	1,336.48	1,333.27
(b) Other current liabilities	2,040.18	391.41
(c) Provisions	654.21	572.08
(d) Current tax liabilities (net)	89.25	4.01
Total current liabilities	10,947.57	8,937.47
Total equity and liabilities	54,469.65	41,134.42



(₹ in million, unless otherwise stated)

Particulars	Year ended	
	31 March 2026	31 March 2025
	Audited	Audited
A. Cash flow from operating activities		
Net profit before tax	3,821.01	3,452.53
Add/ less: non-cash adjustments		
Depreciation and amortisation expense	1,545.51	1,534.46
Bad debts	1.20	2.34
Provision for expected credit loss on trade receivable	293.01	291.77
Provision on advance to suppliers	12.77	31.00
Liabilities no longer required, written back	(38.06)	(79.54)
Unrealized foreign exchange differences (net)	(15.72)	7.51
(Gain)/loss on sale of property, plant and equipment (net)	0.55	1.12
Reversal of losses incurred due to floods	-	(88.62)
Finance costs	940.73	346.00
Gain on reassessment of right-of-use assets	(0.63)	(38.27)
Fair value changes on financial instruments	-	(38.67)
Employee discount on issue of shares	-	15.60
Income tax refund receivable	-	(19.25)
Interest income	(1,096.77)	(249.86)
Operating profit before working capital changes	5,463.60	5,168.12
Adjustments for working capital changes		
Increase in inventories	(747.82)	(505.71)
(Increase)/decrease in trade receivables	(522.57)	342.14
Increase in other assets	(782.73)	(493.00)
(Decrease)/increase in trade payables	(297.43)	1,152.70
Increase in other financial liabilities	69.49	626.08
Increase in provisions	222.39	41.20
Increase/(decrease) in other liabilities	9,280.77	(867.23)
Cash flow generated from operations (gross)	12,685.70	5,464.31
Less: direct taxes paid (net)	(873.68)	(812.35)
Net cash flow generated from operating activities (A)	11,812.02	4,651.96
B. Cash flow from investing activities		
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress, capital advances and payable towards property, plant and equipment)	(2,305.29)	(2,723.12)
Proceeds from sale of property, plant and equipment	77.48	85.47
Investment in deposits having original maturity of more than 3 months, (net)	(7,461.19)	(3,090.64)
Consideration paid to NCI towards further acquisition of interest in subsidiary	(0.25)	-
Interest received	386.57	249.86
Net cash flow used in investing activities (B)	(9,302.68)	(5,478.43)
C. Cash flow from financing activities		
Proceeds from issue of shares (net of share issue expenses)	-	6,373.70
Repayments of non-current borrowings	-	(1,238.60)
Proceeds/ (repayment of) from current borrowings (net)	592.99	(3,540.40)
Payment of principal components of lease liabilities	(93.70)	(521.74)
Payment of interest components of lease liabilities	(69.18)	(62.44)
Interest paid	(91.31)	(282.64)
Net cash flow generated from financing activities (C)	338.80	727.88
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	2,848.14	(98.59)
Cash and cash equivalents as at the beginning of the year	1,011.91	1,110.50
Cash and cash equivalents as at the end of the year	3,860.05	1,011.91

Note: The above unaudited consolidated statement of cash flows has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7 - Statement of Cash Flows.



Notes :

- The above consolidated financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 14 May 2026. These consolidated financial results for the quarter and year ended 31 March 2026 have been audited by statutory auditor and they have issued an unmodified report on the aforementioned results.
- The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures for the respective full financial years ended 31 March 2026 and 31 March 2025 and unaudited published figures upto the nine months periods of the respective financial years, which were subject to the limited review by statutory auditors of the Holding Company.
- The above consolidated financial results of Akums Drugs and Pharmaceuticals Limited (the 'Holding Company' or 'Parent'), together with its subsidiaries (collectively the 'Group') have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).
- The Holding Company had completed its Initial Public Offer (IPO) of 27,368,143 equity shares of face value of ₹ 2 each at an issue price of ₹ 679 per share (including share premium of ₹ 677 per share). A discount of ₹ 64 per share was offered to eligible employees bidding in the employee reservation portion of 243,826 equity shares. Pursuant to IPO, the equity shares of the Holding Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 6 August 2024. The issue comprised of fresh issue of 10,037,708 equity shares aggregating to ₹ 6,800.00 million and offer for sale of 17,330,435 equity shares by selling shareholders, aggregating to ₹ 11,767.37 million.

IPO related expenses were earlier estimated at ₹ 1,116.58 million and were allocated between the Holding Company and the selling shareholders in proportion to their respective shares in the issue. The Holding Company, during the quarter ended 31 March 2026 had incurred IPO expenses amounted to ₹ 990.61 million till date as against the earlier estimated expenses of ₹ 1,116.58 million as disclosed in the Prospectus, resulting in an excess provision of ₹ 125.98 million. The IPO expenses were initially withheld from the IPO proceeds and were allocated between the Holding Company and the selling shareholders in proportion to their respective shares in the issue. Accordingly, the excess amount of ₹ 125.98 million is being released proportionately to the Holding Company and the selling shareholders.

Pursuant to the Board resolution dated 13 February 2026, out of the excess amount attributable to the Holding Company, ₹ 48.10 million has been reallocated towards the objects of the issue, comprising ₹ 23.10 million towards pursuing inorganic growth initiatives through acquisitions and ₹ 25.00 million towards general corporate purposes. The balance amount attributable to the selling shareholders is being released to them in proportion to their respective entitlements. Accordingly, the utilisation of the net IPO proceeds, after the aforesaid reallocation, is summarised below:

Objects	Revised net proceeds as per prospectus*	Actual net proceeds*	Utilisation upto 31 March 2026	Unutilised amount as on 31 March 2026
Repayment/prepayment of all or certain borrowings of Holding Company	1,599.10	1,599.10	1,599.10	-
Repayment/prepayment of all or certain borrowings of subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2,270.90	2,270.90	2,270.90	-
Funding incremental working capital requirements of Holding Company	550.00	550.00	550.00	-
Pursuing inorganic growth initiatives through acquisitions	301.80	301.80	278.70	23.10
General corporate purposes	1,700.00	1,700.00	1,675.00	25.00
Total proceeds (net of IPO expenses)	6,421.80	6,421.80	6,373.70	48.10

* includes ₹ 48.10 million arising from the reallocation of excess IPO expenses provision as explained above, resulting in a corresponding increase in the actual net proceeds available for utilisation.

- The Akums Employee Benefit Trust ("ESOP Trust") has been treated as an extension of the Holding Company and accordingly, shares held by ESOP Trust are netted off from the paid up share capital and calculation of earnings per share (basic and diluted) have been done accordingly. Further, all the assets, liabilities, income and expenses of the trust are accounted for as assets, liabilities, income and expenses of the Holding Company.
- Finance costs include ₹197.27 million and ₹776.06 million recognized in the consolidated financial results for the quarter and year ended 31 March 2026 respectively in respect of a long-term customer advance, representing the unwinding of a significant financing component under Ind AS 115. This notional interest expense has also resulted in the recognition of a deferred tax asset amounting to ₹49.65 million and ₹195.32 million for the quarter and year ended 31 March 2026 respectively.
- During the quarter and year ended 31 March 2026, the Company recognised exceptional items comprising the following:

Particulars	Quarter ended			Year ended	
	31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
Impact of changes in labour code (refer note (a) below)	(20.16)	182.28	-	162.12	-
Retrospective wage revision/ variable dearness allowance (VDA) arrears (refer note (b) below)	38.12	-	-	38.12	-
Reversal of losses incurred due to floods	-	-	(82.17)	-	(166.97)
Total	17.96	182.28	(82.17)	200.24	(166.97)



(a) On 21 November 2025, the Government of India notified the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020, thereby consolidating 29 existing labour laws. The Group has assessed the incremental impact of these changes. Considering the material and non-recurring nature of the impact, net reversal of Rs. 20.16 million relating to gratuity and compensated absences has been disclosed under 'Exceptional items' in these consolidated financial results for the quarter and year ended 31 March 2026. The Group will continue to evaluate the impact of future regulatory clarifications and Rules.

(b) Subsequent to the quarter and year ended 31 March 2026, the Government of Uttarakhand revised the Variable Dearness Allowance ("VDA") rates for scheduled employments with retrospective effect. Accordingly, the cumulative impact relating to prior periods has been recognised as a liability as at 31 March 2026 and disclosed under 'Exceptional items' in these consolidated financial results for the quarter and year ended 31 March 2026.

8 During the financial year ended 31 March 2025, from 15 January 2025 to 21 January 2025, the Income Tax Department ("IT Department") has conducted a search and seizure operation under Section 132 of the Income Tax Act, 1961, at certain offices and manufacturing units of the Holding Company and its subsidiaries, and the residences of select key managerial personnel of the Group.

During the search and seizure proceedings, the Group has fully cooperated, provided the required information and responses to the IT Department. As a part of search and seizure operation, the IT Department has cloned electronic books of accounts, laptops, data backups and seized certain documents, cash and other materials for further investigation. The business and operations of the Group continued without any disruptions, except some minor operational hiccups, and customer commitments were met during this period. During the current year, the Holding Company and certain subsidiaries has received notices under Section 158BC of the Income tax Act, 1961, which requires the Group Companies, in consequence of aforesaid search and seizure operations initiated under Section 132, to furnish returns of undisclosed income for the relevant block period from 01 April 2018 to 12 March 2025 in the prescribed form and manner as per rule 12AE of Income-tax Rules, 1962 setting forth such other particulars as may be prescribed by the Income-tax Act, 1961 within 60 days from the date of notice. The Holding Company and its certain subsidiaries have assessed that no undisclosed income is required to be reported and accordingly, have filled the said returns during the year. Further, the Holding Company and its certain subsidiaries have received notices under Section 142(1)/143(2) of the Income Tax Act, 1961 to furnish accounts or documents or information in response thereto for the aforesaid block period for which notices have been issued. The Holding Company and its certain subsidiaries have submitted the said details in compliance to the said notices.

Subsequent to the quarter/year ended 31 March 2026, the Holding Company and few of its subsidiaries have received show cause notices (SCN) till date, in relation to the ongoing block assessment proceedings under section 158BC of the Income Tax Act, 1961 for the block period in relation to certain disallowance of expenses for which the Holding Company and its subsidiaries are in the process of submitting its response to the IT Department.

Further, there have been no demands which have been raised on the Group as of date. Based on the foregoing and having regard to the matters of the inquiry during the search and seizure proceedings stated above including the SCN and the legal opinion obtained by the management for matters of admissibility under Income Tax Act, 1961, as applicable, while the proceedings are ongoing by the IT Department, the management is of the view that no material adjustments are required to these consolidated financial results/statements for the quarter and year ended 31 March 2026/ year ended 31 March 2026 in this regard.

9 The Board of Directors at its meeting held on 14 May 2026 has recommended a final dividend of ₹ 1 per equity share and special dividend of ₹ 2 per equity share for the year ended 31 March 2026, subject to the approval of shareholders at the ensuing Annual General Meeting.



Place: New Delhi
Date: 14 May 2026



For and on behalf of Board of Directors of
Akums Drugs and Pharmaceuticals Limited

Sanjeev Jain
Managing Director
DIN: 00323433

AKUMS
DRUGS & PHARMACEUTICALS LTD.

Plot No. 131 to 133, Block-C, Mangolpur Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

+91-11-69041000

CIN: L24239DL2004PLC125888

www.akums.in

akumsho@akums.net

+91-11-27023256



Annexure A1

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Symbol: AKUMS

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Mumbai - 400 001
Scrip Code: 544222

Sub: Declaration of Un-Modified Opinion on Annual Audited (standalone and consolidated) Financial Results for the financial year ended March 31, 2026.

Respected Sir/Madam,

In terms of applicable provisions of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, I hereby confirm and declare that the Statutory Auditors, Walker Chandio & Co. LLP, have given unmodified opinion on the Annual Audited (standalone and consolidated) Financial Results of the Company for the financial year ended 31st March, 2026.

For Akums Drugs and Pharmaceuticals Limited

Sumeet Sood
Chief Financial Officer



Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

AKUMS

DRUGS & PHARMACEUTICALS LTD.



Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

www.akums.in

akumsho@akums.net

+91-11-69041000

CIN: L24239DL2004PLC125888

+91-11-27023256

Statement of Deviation / Variation in utilisation of funds Raised						
Name of listed entity	Akums Drugs and Pharmaceuticals Limited					
Mode of Fund Raising	Public Issues					
Date of Raising Funds	August 2, 2024 (Listed on August 6, 2024 on BSE Limited and National Stock Exchange of India Limited)					
Amount Raised	6800.00 million					
Report filed for Quarter ended	31-03-2026					
Monitoring Agency	Applicable					
Monitoring Agency Name, if applicable	CRISIL Ratings Limited					
Is there a Deviation / Variation in use of funds raised	No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable					
If Yes, Date of shareholder Approval	Not Applicable					
Explanation for the Deviation / Variation	Not Applicable					
Comments of the Audit Committee after review	No Comments					
Comments of the auditors, if any	No Comments					
Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation**	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Repayment/ prepayment of indebtedness of the Company	Not Applicable	1,599.10	0	1,599.10	No deviation/variation in utilization of funds raised through IPO	-
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	Not Applicable	2,270.90	0	2,270.90		-
Funding incremental working capital requirements of our Company	Not Applicable	550.00	0	550.00		-
Pursuing inorganic growth initiatives through acquisitions	Not Applicable	278.70	301.80***	278.70		-
General corporate purposes (GCP)*	Not Applicable	1,675.00	1,700.00***	1,675.00		-

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

AKUMS DRUGS & PHARMACEUTICALS LTD.



Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

www.akums.in

akumsho@akums.net

+91-11-69041000

CIN: L24239DL2004PLC125888

+91-11-27023256

*The amount utilized for general corporate purposes does not exceed 25% of the Gross Proceeds (amounting to Rs 1700.00 million) from the Fresh Issue.

** The amount of original allocation represents the amount raised through fresh Issue net of offer expenses as mentioned in the prospectus dated August 1, 2024.

***During the quarter ended March 31, 2026, unutilised issue expenses of Rs 48.10 million has been allocated towards the object of - "GCP" by Rs 25 million & "Pursuing inorganic growth initiatives through acquisitions" by Rs 23.10 million as actual utilization towards issue expenses is lower than the proposed deployment resulting in an increase in net proceeds. The allocation of proceeds was duly approved by the Board of Directors of the Company through a resolution dated 13th February 2026.

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc


Sumet Sood
Chief Financial Officer

Date: 14.05.2026

Place: Delhi

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

Annexure - C

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular vide No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Particulars	Details
1.	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment of M/s. Balwinder & Associates, Cost Accountants (FRN: 000201) as Cost Auditors of the Company
2.	date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Re-appointed in the Board Meeting held on May 14, 2026 for the F.Y. 2026-27
3.	brief profile (in case of appointment);	M/s. Balwinder & Associates, Cost Accountants is a professional firm providing wide range of cost & management advisory and other compliance services and specialises in delivering integrating, technology - enabled solutions in the areas of costing and management.
4.	disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Annexure - D

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular vide No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Particulars	Details
1.	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of Mahajan & Aibara LLP, Chartered Accountants as Internal Auditors of the Company
2.	date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Appointed in the Board Meeting held on May 14, 2026 for the F.Y. 2026-27
3.	brief profile (in case of appointment);	<p>Mahajan & Aibara is a specialist firm providing Internal Audit Services to multiple Indian Corporates, MNCs & large business houses across India & Middle East.</p> <p>The firm is led by 10 Partners and having multidisciplinary staff strength of 300+ professionals across the country. They have significant experience in Service Industry as well as manufacturing sector across wide spectrum of clients. Their capability and prior experience with the group will smoothly engrain them into our system to add tangible value to our organization.</p>
4.	disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Annexure - E

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular vide No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Particulars	Mr. V Jagannathan, President - HR	Mr. Arvind Srivastava, President - HR
1.	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment as Senior Management Personnel	Cessation as Senior Management Personnel This cessation is caused, due to some structural changes in the Company
2.	date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	w.e.f. May 14, 2026	From the close of the business hours of May 14, 2026
3.	brief profile (in case of appointment);	Mr. Jagannathan holds M.S.W, Personnel Management & Industrial Relations, SRKV CAS (Bharathiyar University), M.Sc. Counselling and Psychotherapy, Talent Management (XLRI), Strategic for CHRO(IIMk) and MBA, Human Resources (Madurai Kamaraj University) and have 24+ Years of vast experience He has rendered his services to Dr. Reddy's, Biocon, Apotex Pharmachem and Piramal Healthcare	Not Applicable
4.	disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable